Hurdles and delays in access to anti-cancer drugs in Europe
Open Access
- 17 November 2014
- journal article
- review article
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 8, 482
Abstract
Ecancermedicalscience is the peer-reviewed open access cancer journal founded by the European Institute of Oncology in Milan. We consider articles on all aspects of research relating to cancer, including molecular biology, genetics, pathophysiology, epideKeywords
This publication has 23 references indexed in Scilit:
- Similarities and Differences in the Oncology Drug Approval Process between FDA and European Union with Emphasis on In Vitro Companion DiagnosticsClinical Cancer Research, 2014
- New drug approval times and safety warnings in the United States and Canada, 1992-2011.2013
- The High Cost of Cancer Drugs and What We Can Do About ItMayo Clinic Proceedings, 2012
- The social value of a QALY: raising the bar or barring the raise?BMC Health Services Research, 2011
- Legislating against Use of Cost-Effectiveness InformationNew England Journal of Medicine, 2010
- The Role of the U.S. Food and Drug Administration Review Process: Clinical Trial Endpoints in OncologyThe Oncologist, 2010
- Emerging Lessons From The Drug Effectiveness Review ProjectHealth Affairs, 2006
- Medicare and Cost-Effectiveness AnalysisNew England Journal of Medicine, 2005
- The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982?2001International Journal of Health Care Finance and Economics, 2005
- Approval of new drugs in the United States. Comparison with the United Kingdom, Germany, and Japan.1996